TRDA

SEC source: 0001689375-23-000077 · wk-form4_1703626507.xml · derivative · entry 8

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,457

Underlying: Common Stock · 2,200 shares

Expires 2030-11-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

F5 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001689375-23-000077 · wk-form4_1703626507.xml · nonDerivative · entry 2

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,571

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.95 to $15.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-23-000077 · wk-form4_1703626507.xml · nonDerivative · entry 1

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,771

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

SEC source: 0001689375-23-000076 · wk-form4_1703281095.xml · nonDerivative · entry 1

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 245,279

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023.

SEC source: 0001689375-23-000075 · wk-form4_1699911333.xml · nonDerivative · entry 1

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 246,279

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023.

SEC source: 0001689375-23-000069 · wk-form4_1697750861.xml · nonDerivative · entry 1

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 247,279

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023.

SEC source: 0001689375-23-000066 · wf-form4_169480928381353.xml · nonDerivative · entry 1

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 248,279

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023.

SEC source: 0001689375-23-000061 · wf-form4_169403443743456.xml · nonDerivative · entry 4

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,168

F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-23-000061 · wf-form4_169403443743456.xml · nonDerivative · entry 3

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,227

F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.88 to $13.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-23-000064 · wf-form4_169403465097330.xml · nonDerivative · entry 4

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,571

F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

SEC source: 0001689375-23-000064 · wf-form4_169403465097330.xml · nonDerivative · entry 3

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,617

F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.01 to $14.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-23-000062 · wf-form4_169403451511634.xml · nonDerivative · entry 4

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,037

F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.

SEC source: 0001689375-23-000062 · wf-form4_169403451511634.xml · nonDerivative · entry 3

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,058

F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-23-000061 · wf-form4_169403443743456.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,140

F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

SEC source: 0001689375-23-000063 · wf-form4_169403458332193.xml · nonDerivative · entry 2

Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,198

F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

SEC source: 0001689375-23-000065 · wf-form4_169403472503735.xml · nonDerivative · entry 2

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 249,279

F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

SEC source: 0001689375-23-000064 · wf-form4_169403465097330.xml · nonDerivative · entry 2

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,521

F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

SEC source: 0001689375-23-000062 · wf-form4_169403451511634.xml · nonDerivative · entry 2

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,929

F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

SEC source: 0001689375-23-000060 · wf-form4_169394589181133.xml · derivative · entry 1

Chapman Gina · CIK 0001989220 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2033-09-01

F1 · derivative.exercise_date: The stock option shall vest in equal monthly installments over three years from the date of grant, subject to the reporting person's continuous service through the applicable vesting date.

SEC source: 0001689375-23-000061 · wf-form4_169403443743456.xml · derivative · entry 5

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,500

Underlying: Common Stock · 21,500 shares

Expires 2033-09-01

F6 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027.

SEC source: 0001689375-23-000061 · wf-form4_169403443743456.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,576

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

SEC source: 0001689375-23-000063 · wf-form4_169403458332193.xml · derivative · entry 3

Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,500

Underlying: Common Stock · 21,500 shares

Expires 2033-09-01

F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027.

SEC source: 0001689375-23-000063 · wf-form4_169403458332193.xml · nonDerivative · entry 1

Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,647

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

SEC source: 0001689375-23-000065 · wf-form4_169403472503735.xml · derivative · entry 3

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,250

Underlying: Common Stock · 75,250 shares

Expires 2033-09-01

F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027.

SEC source: 0001689375-23-000065 · wf-form4_169403472503735.xml · nonDerivative · entry 1

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,719

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

SEC source: 0001689375-23-000064 · wf-form4_169403465097330.xml · derivative · entry 5

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,500

Underlying: Common Stock · 21,500 shares

Expires 2033-09-01

F5 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027.

SEC source: 0001689375-23-000064 · wf-form4_169403465097330.xml · nonDerivative · entry 1

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,947

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

SEC source: 0001689375-23-000062 · wf-form4_169403451511634.xml · derivative · entry 5

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,500

Underlying: Common Stock · 21,500 shares

Expires 2033-09-01

F5 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027.

SEC source: 0001689375-23-000062 · wf-form4_169403451511634.xml · nonDerivative · entry 1

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,330

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

SEC source: 0001689375-23-000056 · wf-form4_169221794370631.xml · nonDerivative · entry 1

Doshi Dipal · CIK 0001613084 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 201,069

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.33 to $16.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · derivative · entry 11

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,012

Underlying: Common Stock · 6,898 shares

Expires 2030-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.

F6 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · nonDerivative · entry 8

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,130

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · nonDerivative · entry 7

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,028

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.

SEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · derivative · entry 10

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 94,910

Underlying: Common Stock · 9,464 shares

Expires 2030-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.

F6 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · nonDerivative · entry 6

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,130

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.44 to $15.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · nonDerivative · entry 5

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,594

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.

SEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · derivative · entry 9

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,374

Underlying: Common Stock · 10,348 shares

Expires 2030-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.

F6 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · nonDerivative · entry 4

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,130

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.

SEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · nonDerivative · entry 3

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,198

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $16.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · nonDerivative · entry 2

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,198

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 to $15.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · nonDerivative · entry 1

KREHER NERISSA · CIK 0001741850 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,478

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.

SEC source: 0001689375-23-000047 · wf-form4_168919399033901.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,376

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-23-000046 · wf-form4_168919391527267.xml · nonDerivative · entry 2

Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 153,447

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-23-000048 · wf-form4_168919407796459.xml · derivative · entry 6

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,657

Underlying: Common Stock · 3,884 shares

Expires 2030-11-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

F4 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001689375-23-000048 · wf-form4_168919407796459.xml · nonDerivative · entry 4

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,747

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.95 to $18.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-23-000048 · wf-form4_168919407796459.xml · nonDerivative · entry 3

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,631

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

SEC source: 0001689375-23-000047 · wf-form4_168919399033901.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,273

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-23-000046 · wf-form4_168919391527267.xml · nonDerivative · entry 1

Sethuraman Natarajan · CIK 0001873394 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,299

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001689375-23-000048 · wf-form4_168919407796459.xml · derivative · entry 5

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,541

Underlying: Common Stock · 6,116 shares

Expires 2030-11-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

F4 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

SEC source: 0001689375-23-000048 · wf-form4_168919407796459.xml · nonDerivative · entry 2

WENTWORTH KORY JAMES · CIK 0001725663 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,747

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.95 to $18.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.